$120.85$150.99
Prepare to embark on a sensory journey with the Bosco Apple, a fruit that transcends the ordinary and promises an unparalleled taste experience. These apples are nothing short of nature’s masterpiece, celebrated for their distinctive blend of flavors and their captivating visual allure.
Availability: In Stock
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
₹3798
INTRODUCTION AFANAT 30 TABLET contains Afatinib, which belongs to a group of medicines called Kinase inhibitors. AFANAT 30 TABLET is used as a first line of management in patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant epidermal growth factor recept...
AFANAT 30 TABLET contains Afatinib, which belongs to a group of medicines called Kinase inhibitors. AFANAT 30 TABLET is used as a first line of management in patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant epidermal growth factor receptor (EGFR) mutations (genetic mutations) in cancer cells, which can be detected by an FDA-approved test.
AFANAT 30 TABLET is also used to manage metastatic squamous non-small cell lung cancer (NSCLC) in patients who might have made some progress with platinum-based chemotherapy (drug therapy used to manage non-small cell lung cancer).
AFANAT 30 TABLET is not recommended for use if you are allergic to Afatinib. Before taking AFANAT 30 TABLET, inform your doctor if you have eye, lung, heart, liver, and/or kidney problems.
AFANAT 30 TABLET is not recommended for use during pregnancy since it may cause harm to the unborn baby. It is also not recommended for use by breastfeeding women since it may pass through breast milk and cause unwanted side effects in breastfed babies.
AFANAT 30 TABLET is also not recommended for use in children and adolescents (aged below 18 years).
The most common side effects of taking AFANAT 30 TABLET are decreased appetite or weight, diarrhea, nausea, vomiting, dry skin, pain or peeling of the skin (hands and feet), and/or stomach pain. Contact your doctor if any of the symptoms get worse.
AFANAT 30 TABLET works by blocking the activity of a group of proteins called ErbB1, ErbB2 (HER2), ErbB3, and ErbB4 in the cancer cells, which are required for the growth and spread of cancer cells, which gets inhibited, resulting in the inhibited growth and spread of the cancer cells.
Take AFANAT 30 TABLET as advised by your physician. Swallow AFANAT 30 TABLET with a glass of water, and do not chew or crush the medicine. Your doctor will decide the correct dose and duration of AFANAT 30 TABLET for you depending upon your age, body weight, and disease condition.
Stop taking AFANAT 30 TABLET and contact your doctor immediately if you experience any of the following side effects:
Drink lots of fluids, such as water, to keep yourself hydrated. Avoid taking any medicine on your own to treat diarrhea. Consult your doctor if the symptom gets worse.
Try to have smaller and more frequent meals and eat and drink slowly. Consult your doctor if symptoms get worse.
Eat when you feel hungry. Eat smaller meals more frequently than usual. Snack only when you're hungry. Eat a nutritious snack that is rich in calories and protein, such as dried fruit and nuts.
Try to take AFANAT 30 TABLET with or just after a meal or a snack. Stick to simple meals. Avoid eating rich or spicy food. Consult the doctor if symptoms get worse.
If AFANAT 30 TABLET causes stomach pain, then try to rest, relax, and have frequent smaller meals. Drink slowly and try to place a covered hot water bottle on your stomach to ease the pain. If your pain persists, then consult your doctor.
AFANAT 30 TABLET is not recommended for use in pregnant women since it may cause fetal harm. Women of childbearing potential should use effective birth control during treatment and for at least 2 weeks after the last dose of AFANAT 30 TABLET.
AFANAT 30 TABLET is not recommended for use in breast-feeding women and for at least 2 weeks after taking the last dose of AFANAT 30 TABLET.
AFANAT 30 TABLET is not recommended for use if you experience symptoms affecting your ability to concentrate and react, such as redness and irritation of the eye, dry eye, tearing, and/or light sensitivity. Consult and inform your doctor before taking AFANAT 30 TABLET.
Avoid consumption of alcohol while taking AFANAT 30 TABLET.
AFANAT 30 TABLET should be used with caution in patients with kidney problems such as severe renal impairment. Consult your doctor for advice before taking AFANAT 30 TABLET.
AFANAT 30 TABLET should be used with caution in patients with liver problems such as severe liver impairment. Consult your doctor for advice before taking AFANAT 30 TABLET.
AFANAT 30 TABLET is not recommended for use if you are allergic to Afatinib or any of the other ingredients of this medicine.
AFANAT 30 TABLET should be taken with caution in patients with lung problems. Consult your doctor before taking it.
AFANAT 30 TABLET should be used with caution in patients with heart problems. Consult your doctor before taking AFANAT 30 TABLET.
AFANAT 30 TABLET is generally not recommended for use in children and adolescents (below 18 years). Consult your doctor before taking AFANAT 30 TABLET.
AFANAT 30 TABLET should be used with caution in elderly patients (aged 65 years or older). Consult your doctor before taking AFANAT 30 TABLET.
Before taking AFANAT 30 TABLET, inform your doctor if you:
A. Drug-Drug Interactions:
Before taking AFANAT 30 TABLET, inform your doctor if you are taking any of the following medicines:
Overdosage:
If you or anyone else accidentally takes more AFANAT 30 TABLET, consult your doctor immediately or visit the nearby hospital. Symptoms of an overdose can be nausea, vomiting, asthenia (physical weakness), dizziness, headache, and abdominal pain.
| Drug | : | Afatinib |
| Pharmacological Category | : | Tyrosine Kinase inhibitor |
| Therapeutic Indication | : | Non-Small Cell Lung Cancer |
| Dosage Forms | : | Tablet |
Q: What is AFANAT 30 TABLET used for?
A: AFANAT 30 TABLET is an anticancer drug used to manage metastatic and squamous non-small cell lung cancer as a first line of management or if prior chemotherapy treatment is insufficient to provide a cure in adult patients. Non-small cell lung cancer (NSCLC) is a type of cancer that occurs in the lung when abnormal cells form and multiply into large, mass-forming tumours or lesions characterized by persistent coughing, shortness of breath, weight loss, or coughing up blood.
Q: How does AFANAT 30 TABLET work on my body?
A: AFANAT 30 TABLET works by blocking the activity of a group of proteins called ErbB1, ErbB2 (HER2), ErbB3, and ErbB4 in the cancer cells, which are required for the growth and spread of cancer cells in the lungs.
Q: What precautions do I need to follow while taking AFANAT 30 TABLET?
A: Patients taking AFANAT 30 TABLET must inform their doctor about their pre-existing disease conditions related to eye, lung, heart, kidney, and liver problems since it may cause some unwanted side effects.
Q: What are the side effects of AFANAT 30 TABLET?
A: The most common side effects of taking AFANAT 30 TABLET are decreased appetite, decreased weight, diarrhea, nausea, vomiting, dry skin, pain or peeling of skin (hands and feet), allergic reactions (such as runny nose, rash, itching, inflammation of the lip, and mouth sores), stomach pain, indigestion, heartburn, eye irritation, and fever. Consult your doctor for advice if your symptoms get worse over time.
Q: Is AFANAT 30 TABLET safe to use with children?
A: No. AFANAT 30 TABLET is not recommended for use in children and adolescents (below 18 years of age). If AFANAT 30 TABLET is accidentally ingested by a child or adolescent, go to the hospital immediately and consult the doctor for further management.
Q: Can AFANAT 30 TABLET be taken by pregnant or breastfeeding women?
A: AFANAT 30 TABLET is not recommended for use in pregnant women since it may cause fetal harm. Women of childbearing potential should use effective birth control during treatment and should continue it for at least 2 weeks after receiving the last dose of AFANAT 30 TABLET. The medicine is not recommended for use in breast-feeding women, and it is advised not to breast-feed while taking AFANAT 30 TABLET and for 2 weeks after taking the last dose of AFANAT 30 TABLET.
1. KD. Tripathi. Chemotherapy Of Neoplastic Diseases. Essentials of medical pharmacology. Seventh edition. 2013. Page – 870.
2. Scott M. Wirth. Afatinib in Non–Small Cell Lung Cancer.NCBI; PMC US National Library of Medicine, National Institute of Health. September 2015 [Accessed on 21st April 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803462/#:~:text=Afatinib%20is%20a%20second%2Dgeneration,and%20HER4%20(ErbB4)%20receptors
3. Boehringer Ingelheim Pharma GmbH & Co. K. Electronic Medicines Compendium (EMC) [Revised in July 2021] [Accessed on 21st April 2022] https://www.medicines.org.uk/emc/files/pil.5147.pdf
4. Boehringer Ingelheim Pharma GmbH & Co. K. Electronic Medicines Compendium (EMC) [Revised in July 2021] [Accessed on 21st April 2022] https://www.medicines.org.uk/emc/files/pil.7701.pdf
5. Boehringer Ingelheim Pharma GmbH & Co. K. Electronic Medicines Compendium (EMC) [Revised in July 2021] [Accessed on 21st April 2022] https://www.medicines.org.uk/emc/files/pil.7699.pdf
6. Boehringer Ingelheim Pharma GmbH & Co. K. Electronic Medicines Compendium (EMC) [Revised in July 2021] [Accessed on 21st April 2022] https://www.medicines.org.uk/emc/files/pil.7698.pdf
7. Boehringer Ingelheim Pharmaceuticals, Inc. U.S. Food & Drug Administration. [Revised in January 2018] [Accessed on 21st April 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf
Written By Dr. N. Sai Swaroop, Pharm.D
Last updated on 27 Nov 2023 | 01:19 PM(IST)